Peptide questions · ARA-290
ARA-290 side effects: what studies and users report
Reviewed Evidence: ModeratePublished by PepVault
The side effects most commonly reported for ARA-290 are injection site reaction, headache and light-headedness, among 5 the library lists; the library’s evidence on it includes controlled trials in people.
Its safety note opens: ARA-290 (cibinetide) is not approved anywhere, and its human safety record is four small randomized phase 2 trials plus one 12-week eye study — on the order of 200 people in total, all run or co-authored by its developer, Araim Pharmaceuticals.
What is commonly reported with ARA-290
- Injection site reaction
- Headache
- Light-headedness
- Fatigue
- Nausea
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 18) |
|---|---|
| Injection site reaction | 6: TB-500, GHK-Cu, AOD-9604, Thymosin Alpha-1 and 2 more |
| Headache | 6: TB-500, Thymosin Beta-4, Linaclotide, VIP and 2 more |
| Light-headedness | None: listed for ARA-290 alone |
| Fatigue | 5: TB-500, Thymosin Alpha-1, Thymosin Beta-4, Abaloparatide and 1 more |
| Nausea | 6: BPC-157, TB-500, AOD-9604, Larazotide and 2 more |

Which ARA-290 side effects the healing & recovery group shares
Across the 19 healing & recovery compounds in the library, the effects listed most often are headache (7 of 19), injection site reaction (7 of 19), nausea (7 of 19) and fatigue (6 of 19). ARA-290 shares 4 of its 5 listed effects with at least one other healing & recovery compound; light-headedness is listed for ARA-290 alone.
What the ARA-290 safety notes say
The library’s safety note
ARA-290 (cibinetide) is not approved anywhere, and its human safety record is four small randomized phase 2 trials plus one 12-week eye study — on the order of 200 people in total, all run or co-authored by its developer, Araim Pharmaceuticals. In the two sarcoidosis trials (22 and 38 patients) blood chemistry and hematology did not change meaningfully; the IV trial noted no adverse events, and the SubQ trial reported no injection-site pain, no serious adverse events through 12 weeks of follow-up and no antibodies against the peptide. In the type 2 diabetes trial (48 analyzed) serious events were few: the investigators judged two possibly related, the one they describe a worsening of already-borderline kidney function after a diuretic dose was raised, and the rest unrelated to the drug. In the 12-week eye study every one of the nine participants had at least one adverse event and none were serious; raised triglycerides, headache, a head cold and raised glucose were the most frequent (fasting was not confirmed, so the lab changes may simply have followed meals), and headache, head cold and nausea were thought possibly drug-related. Across more than 200 people treated, one with a prior history of depression had suicidal thoughts during treatment. By design it does not stimulate red-cell production — it was not erythropoietic in lab or animal tests — which is the whole point of the molecule next to EPO itself. For athletes: the 2026 WADA list prohibits innate repair receptor agonists as a class at all times (its examples are asialo EPO and carbamylated EPO), and the list covers substances of similar biological effect; ARA-290 was dropped as a named example in 2018. Discuss with your clinician; long-term human safety is unestablished.
The library’s interaction note
No human drug-interaction study of ARA-290 has been published. The trials let participants keep their usual medication — analgesics and immune suppressants in sarcoidosis, and everything from no drugs to intensive insulin in diabetes — and most participants' medication was unchanged through the dosing period. In the diabetes trial HbA1c, triglycerides and the cholesterol-to-HDL ratio all moved over 28 days, so anyone on glucose- or lipid-lowering treatment has numbers a clinician would want to watch. Unlike EPO it does not raise red cells, so EPO's clotting concerns do not carry over, but that has only been checked over weeks. Discuss any prescription medications with your clinician.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Where the ARA-290 reports come from
The library rates the evidence on ARA-290 as moderate: animal studies plus some human data.
Of the library’s 6 research notes on ARA-290, 3 rest on randomized trials, 1 on clinical data and 2 on community reports.
Our 5 study pages on ARA-290: 4 randomized trials and 1 animal study (rats).
So ARA-290 has controlled trials in people to set its listed effects against.
What our ARA-290 study pages report on safety
ARA-290 improved small fiber neuropathy symptoms in sarcoidosis
Randomized trial, human, 2012: Clinical exams and lab tests turned up no safety problems. This early, small human trial found ARA-290 well tolerated in sarcoidosis, with better neuropathy symptom scores than placebo but no edge on pain ratings.
Questions people ask
What are the side effects of ARA-290?
The side effects most commonly reported for ARA-290 are injection site reaction, headache and light-headedness, among 5 the library lists; the library’s evidence on it includes controlled trials in people.
Do ARA-290’s side effects come from human studies?
The library rates the evidence on ARA-290 as moderate, and the library’s evidence on it includes controlled trials in people.
Which ARA-290 side effects are its own?
Among the healing & recovery compounds, the library lists light-headedness for ARA-290 alone.
Does ARA-290 interact with other medicines?
The library’s interaction note on ARA-290 begins: No human drug-interaction study of ARA-290 has been published.